Physician profile
James W Robb
NPI 1447645940
$3,089.41
in general payments reported to CMS, 2019-2025
29 companies · $701 in 2025
The $701 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.54 · 2020: $122 · 2021: $487 · 2022: $683 · 2023: $520 · 2024: $559 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,780.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $312.03 | 2021-2025 | |
| Biogen, INC. | $307.72 | 2024-2025 | Zurzuvae |
| Minerva Surgical, INC | $285.50 | 2021-2025 | |
| Abbvie INC. | $283.45 | 2020-2023 | Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $249.42 | 2021-2025 | |
| Astellas Pharma US INC | $190.25 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $185.93 | 2021-2022 | |
| Pfizer INC. | $181.45 | 2019-2024 | |
| Organon LLC | $139.19 | 2021-2025 | Nexplanon |
| Evofem Biosciences, INC. | $104.31 | 2021-2022 | |
| Hologic Sales and Service, LLC | $99.82 | 2021-2025 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $91.55 | 2023-2024 | Myfembree |
| Shield Therapeutics INC | $80.76 | 2023-2025 | Accrufer |
| Intuitive Surgical, INC. | $71.57 | 2023 | Da Vinci Surgical System |
| Exeltis, USA INC. | $68.52 | 2021-2024 | Slynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $61.74 | 2021-2022 | |
| Therapeuticsmd, INC. | $53.25 | 2020-2022 | |
| Amgen INC. | $45.20 | 2023 | Prolia, Evenity |
| Smith+Nephew, INC. | $43.36 | 2025 | Stravix |
| Kci USA, INC. | $32.26 | 2021-2023 | Prevena |
| Novo Nordisk INC | $29.13 | 2020-2023 | Wegovy, Saxenda |
| Innovation Technologies INC | $27.26 | 2025 | Irrisept |
| Merck Sharp & Dohme LLC | $26.96 | 2020-2021 | |
| Ethicon US, LLC | $23.67 | 2021 | |
| Millicent US INC | $23.10 | 2025 | Intrarosa, Femlyv |
| Coloplast Corp | $21.27 | 2022 | |
| Teleflex LLC | $20.63 | 2025 | Kmedic |
| Lupin INC. | $16.22 | 2020 | |
| Allergan, INC. | $13.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.